Published online Jun 14, 2013. doi: 10.3748/wjg.v19.i22.3487
Revised: May 15, 2013
Accepted: May 22, 2013
Published online: June 14, 2013
Core tip: This is a well conducted experimental study on the possible effect of nesfatin-1 in visceral hypersensitivity. Currently no reports have been published concerning the role of nesfatin-1 in irritable bowel syndrome (IBS). In a well-established visceral hypersensitivity animal model, we found an elevated nesfatin-1 level in the serum, and there was a reduction in evoked abdominal electromyography and abdominal withdrawal reflex scores after treatment with nesfatin-1 antibody, a non-selective corticotropin releasing factor (CRF) receptor antagonist, or a selective CRF1 receptor antagonist. These results suggest that nesfatin-1 may be associated with visceral hypersensitivity in model rats and implicated in brain CRF/CRF1 signaling pathways, which contribute to the visceral hypersensitivity of IBS.